196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data Article Swipe

MAKE IMPACT

Nayan Lamba , Bryan Iorgulescu · YOU? · · 2020 · Open Access · · DOI: https://doi.org/10.1136/jitc-2020-sitc2020.0196

Background Management of advanced non-small cell lung carcinoma (NSCLC) has been transformed by PD-1/PD-L1 immune checkpoint inhibitors (ICI), with FDA approvals in 2015 (second-line) and 2016 (first-line). Despite ~40% of NSCLC patients developing brain metastases, these patients were disproportionately excluded from the pioneering ICI trials. Thus herein we evaluate the overall survival (OS) associated with ICI in NSCLC brain metastases nationally. Methods Patients newly-diagnosed with stage 4 NSCLC, including brain metastases, from 2010–2016 were identified from the National Cancer Database (comprising >70% of all newly-diagnosed cancers in the U.S.) Landmark survival analysis was used to address immortal time bias. Post-approval, median time from diagnosis to ICI was 58 days, and this timepoint was selected for all landmark survival analyses (OS estimated by Kaplan-Meier technique, and compared by logrank test and multivariable Cox regression) and for multivariable logistic regression to identify predictors of ICI utilization. Results 50,858 patients presented with advanced NSCLC that involved the brain: representing 27.6% of all newly-diagnosed stage 4 cases. Following initial FDA approvals in 2015, ICI use in brain metastasis patients rose from 7.2% in 2015 to 12.7% in 2016. OS for NSCLC brain metastasis patients diagnosed post-approval (i.e. 2015, median 6.3 months, 95% [confidence interval] CI: 6.0–6.6) was substantially better than those diagnosed pre-approval (median 5.5 months, 95%CI: 5.4–5.7, p<0.001) and, in fact, than those diagnosed in 2014 (median 5.9 months, 95%CI: 5.6–6.1, p=0.002). Among patients diagnosed post-approval (in 2015, n=7,431), ICI receipt demonstrated substantially improved OS in landmark survival analyses (median 13.8 months, 95%CI: 12.2–15.1; vs. 8.5 months, 95%CI: 8.3–8.9, p<0.001) – benefits which persisted in multivariable landmark survival analyses (hazard ratio [HR] 0.83, 95%CI: 0.71–0.96, p=0.02), independent of patient characteristics, other therapies, and extracranial disease. For patients diagnosed post-approval, who reached the landmark timepoint, ICI receipt was independent of patient demographics, socioeconomic status, and hospital type—with the exception of Medicaid-insured patients, who were less likely than privately insured patients to receive ICI (OR 0.77, 95%CI: 0.60–0.97, p=0.03). Conclusions Nationally, the use of ICI for NSCLC brain metastasis patients is increasing, generally without significant socioeconomic barriers. Brain metastasis patients diagnosed in the post-approval second-line ICI era (2015) demonstrated significantly better OS than patients diagnosed pre-approval and even than patients diagnosed only in 2014. ICI was associated with a >60% relative increase in median OS. Together our findings from a real-world population demonstrate that the dramatic OS benefits of ICIs for advanced NSCLC also extended to brain metastasis patients.

Type

article

Language

en

Landing Page

https://doi.org/10.1136/jitc-2020-sitc2020.0196

OA Status

hybrid

Cited By

1

Related Works

10

OpenAlex ID

https://openalex.org/W3100532580

Raw OpenAlex JSON

OpenAlex ID

https://openalex.org/W3100532580

Canonical identifier for this work in OpenAlex

DOI

https://doi.org/10.1136/jitc-2020-sitc2020.0196

Digital Object Identifier

Title

196 Checkpoint blockade therapy for brain-metastatic non-small cell lung cancer: a comparative effectiveness analysis of national data

Work title

Type

article

OpenAlex work type

Language

en

Primary language

Publication year

2020

Year of publication

Publication date

2020-11-01

Full publication date if available

Authors

Nayan Lamba, Bryan Iorgulescu

List of authors in order

Landing page

https://doi.org/10.1136/jitc-2020-sitc2020.0196

Publisher landing page

Open access

Yes

Whether a free full text is available

OA status

hybrid

Open access status per OpenAlex

OA URL

https://doi.org/10.1136/jitc-2020-sitc2020.0196

Direct OA link when available

Concepts

Medicine, Brain metastasis, Oncology, Internal medicine, Lung cancer, Proportional hazards model, Confidence interval, Cancer, Stage (stratigraphy), Metastasis, Biology, Paleontology

Top concepts (fields/topics) attached by OpenAlex

Cited by

1

Total citation count in OpenAlex

Citations by year (recent)

2025: 1

Per-year citation counts (last 5 years)

Related works (count)

10

Other works algorithmically related by OpenAlex

Full payload